Praxis Precision Medicines
PRAX
300.43
-10.47
-3.37%
Praxis Precision Medicines
US · PRAX
#1645 by market cap
Listed 2020
300.43
-10.47
-3.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Company notice
Adways: Adways has begun operating "PRAX," an AI solution that leverages its accumulated expertise in promotional proposal services.JPX · 2026/11/5
-
Rating change
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945Market Newswire · 2026/8/17
-
Rating change
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650Market Newswire · 2026/8/18
-
Rating change
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $534Market Newswire · 2026/10/2
-
Rating change
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $582Market Newswire · 2026/9/24
-
Rating change
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $575Market Newswire · 2026/8/21
-
Rating change
J.P. Morgan Initiates Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $700Market Newswire · 2026/10/16
-
Rating change
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754Market Newswire · 2026/8/8
-
Praxis Precision Medicines (PRAX.US) will release its financial report before the market opens on November 9.Market Newswire · 2026/11/4
-
Rating change
BTIG Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $826Market Newswire · 2026/10/6
-
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $343 to $1,201Market Newswire · 2026/11/11
-
Rating change
BTIG Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $826Market Newswire · 2026/11/3
-
RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $478Market Newswire · 2026/11/14
-
Rating change
Goldman Sachs Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $575Market Newswire · 2026/8/20
-
Rating change
UBS Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $706Market Newswire · 2026/10/15
-
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200Market Newswire · 2026/11/13
-
Company notice
Praxis Precision Medicines: Praxis Precision Medicines, Inc. - Reverse Split Option Symbol: PRAX New Symbol: PRAX1OCC · 2023/11/28
-
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201Market Newswire · 2026/11/13
-
Rating change
UBS Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $706Market Newswire · 2026/10/15
-
Rating change
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)TipRanks · 2026/10/6
-
Rating change
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800Market Newswire · 2026/8/7
-
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200Market Newswire · 2026/10/22
-
Rating change
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201Market Newswire · 2026/8/8
-
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201Market Newswire · 2026/10/15
-
Rating change
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $719Market Newswire · 2026/7/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.
Praxis Precision Medicines discussion 0 comments